BGI Dx, Bioscience Genomics Ink NIPT Deal


UPDATE: Danaher Q3 Revenues Improve 4 Percent


Alnylam Stock Jumps on Positive Phase II ATTR Drug Data


Arrowhead Sued over Stock Drop Linked to Clinical Data on HBV Drug Candidate


With RNAi Screening Tech, Startup Recursion Aims to Repurpose Drugs for Rare Diseases


Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic


Nitto Denko Advances RNAi Fibrosis Drug into Phase Ib


Alnylam Presents Animal Data on siRNA Delivery via Inhalation, Adds PH1 to Pipeline


IP Update: Recent Patents Awarded to Alnylam, Quark, Qiagen, and More


NIAID Awards Consortium $6.5M to Investigate S. Aureus